Cálculos Biliares

Andrographis (Andrographis paniculata) is widely used in integrative Lyme disease protocols for its potent anti-inflammatory and immune-modulating properties via andrographolide. While a 2020 Johns Hopkins in vitro study found it did not directly inhibit B. burgdorferi, it is included in a comprehensive 2023 PMC review of 18 Lyme-relevant herbs. Traditional and clinical use focuses on immune support and anti-inflammatory action for persistent Lyme symptoms.

Andrographolide, the primary bioactive diterpene lactone of Andrographis paniculata, drives the herb's potent NF-κB inhibition and anti-inflammatory effects relevant to chronic Lyme disease. It is central to Lyme integrative protocols for immune modulation and cytokine reduction. Research has shown it can modulate host immune responses potentially impacting B. burgdorferi clearance. Evidence is primarily mechanistic and in vitro.

Astragalus (Astragalus membranaceus) was included in the 2023 University of Maryland comprehensive review as one of 13 herbs with in vitro antimicrobial activity relevant to Lyme disease, plus potent immunomodulatory properties. It enhances T-cell and natural killer cell activity potentially relevant to B. burgdorferi clearance. Used in TCM for immune strengthening and widely incorporated into integrative Lyme protocols. No Lyme-specific clinical trials exist.

Baicalein is a bioactive flavonoid from Scutellaria baicalensis (Baikal Skullcap) with documented in vitro activity against all morphological forms of B. burgdorferi and B. garinii, including spirochete, rounded, and biofilm forms. It was confirmed as the most effective phytochemical against biofilm-forming Borrelia in a 2015 PMC study. Additional neuroprotective effects are relevant to neurological Lyme manifestations.

Baicalin, the glycoside form of baicalein from Scutellaria baicalensis, has in vitro activity against B. burgdorferi and B. garinii, including biofilm and rounded forms, as documented in PMC studies. It has anti-inflammatory activity via NF-κB inhibition confirmed in multiple in vitro studies. Baicalin also has documented neuroprotective effects relevant to neurological Lyme disease manifestations.

Baikal Skullcap (Scutellaria baicalensis) and its flavonoid baicalein demonstrated in vitro anti-borrelia activity against multiple morphological forms of B. burgdorferi and B. garinii, including biofilm. It was among the 7 most active botanicals in the 2020 Johns Hopkins in vitro study. Active constituents baicalin and baicalein also have documented neuroprotective and anti-inflammatory effects relevant to neurological Lyme. Employed in Traditional Chinese Medicine for over 2,000 years.

Berberine, an isoquinoline alkaloid found in goldenseal, barberry, and Coptis, was included in the 2023 University of Maryland review as one of 13 herbs with in vitro antimicrobial activity relevant to Lyme disease. It modulates gut microbiome dysbiosis and intestinal barrier function, both commonly disrupted in chronic Lyme. It has anti-inflammatory activity via NF-κB inhibition. No clinical trials exist specifically for Lyme disease.

Black walnut (Juglans nigra) was identified as one of seven botanicals with superior in vitro activity against stationary-phase B. burgdorferi in the 2020 Johns Hopkins Frontiers in Medicine study. Its active constituents include juglone (naphthoquinone) with documented antimicrobial properties. Evidence is currently limited to in vitro data. Clinical use comes from integrative Lyme practitioners, notably the Buhner herbal protocol.

Cat's claw (Uncaria tomentosa) extract has demonstrated in vitro inhibitory activity against growing and stationary-phase (persister) forms of Borrelia burgdorferi, outperforming standard antibiotics doxycycline and cefuroxime in a 2020 Johns Hopkins study. It also has immunomodulatory and anti-inflammatory properties relevant to chronic Lyme symptoms. A small clinical study of 28 advanced Lyme patients showed potential benefit. Oxindole alkaloids and quinovic acid glycosides are its primary bioactive constituents.

Cistus (Cistus incanus, Mediterranean rockrose) was one of seven botanicals shown to exceed doxycycline and cefuroxime against stationary-phase B. burgdorferi in the 2020 Johns Hopkins in vitro study. It also inhibits biofilm formation without harming healthy cells. Its polyphenol-rich extract is used in integrative Lyme protocols, particularly in Europe. Evidence remains at in vitro level.

Cordyceps (Cordyceps sinensis) was one of 18 herbs reviewed in the 2023 University of Maryland narrative review for persistent Lyme disease symptoms, showing in vitro antimicrobial activity and potent immunomodulatory and anti-inflammatory properties. It is used in integrative Lyme protocols, particularly the Rawls protocol, for immune modulation and fatigue reduction. No Lyme-specific clinical trials exist.

Japanese knotweed root (Polygonum cuspidatum) was one of the two most potent botanicals against B. burgdorferi in the 2020 Johns Hopkins in vitro study, with the lowest MIC values. Its active compounds resveratrol and emodin exhibit direct anti-borrelia, anti-inflammatory, neuroprotective, and blood-brain barrier-penetrating properties. It has been a central herb in the Buhner Lyme protocol. Evidence is primarily in vitro with no clinical trials completed.

Eleuthero (Eleutherococcus senticosus, Siberian ginseng) was one of 18 herbs included in the 2023 University of Maryland Lyme disease narrative review. It is used in integrative Lyme protocols as an adaptogen to restore immune function, stamina, and stress resilience depleted by chronic Lyme. It also promotes lymphatic circulation. Limited anti-borrelia in vitro activity was found; its value is primarily immunomodulatory and adaptogenic.

Garlic and its active constituent allicin have demonstrated in vitro antimicrobial activity against B. burgdorferi. The 2023 University of Maryland narrative review included garlic among 13 herbs with in vitro antimicrobial activity relevant to Lyme disease. It has also been studied for activity against persister forms of B. burgdorferi. Research shows broad-spectrum antimicrobial and anti-inflammatory properties. No human Lyme clinical trials exist.

Garlic bulb (Allium sativum) contains allicin and related organosulfur compounds with documented in vitro antimicrobial activity against B. burgdorferi. It appears in comprehensive reviews of herbal supplements used for persistent Lyme disease symptoms. Its anti-inflammatory and immune-modulating properties are also relevant. Used extensively in integrative Lyme disease management protocols.

A Johns Hopkins Bloomberg School of Public Health in vitro study (published in Frontiers in Medicine) found Japanese knotweed among the most active plant extracts against Borrelia burgdorferi, including dormant persister forms not killed by standard antibiotics. Knotweed outperformed doxycycline and cefuroxime in this screen. A 2021 study further demonstrated activity against Bartonella. Evidence is in vitro only; no human RCTs exist.

Lemon balm (Melissa officinalis) was included in the 2023 University of Maryland comprehensive narrative review of 18 herbal supplements for persistent Lyme symptoms, showing in vitro antimicrobial activity. It is used in integrative Lyme protocols primarily for its antiviral and anxiolytic properties addressing neurological and mood-related Lyme symptoms. Active rosmarinic acid and flavonoids provide anti-inflammatory and antiviral mechanisms.

Luteolin, a widely distributed flavone, demonstrated in vitro bacteriostatic and bactericidal activity against B. burgdorferi spirochetes in a 2016 PMC study, and reduced biofilm-like colonies at 200–500 µg/ml. It also has potent NF-κB-mediated anti-inflammatory effects relevant to chronic Lyme symptoms. It is present in Thyme, lemon balm, and other Lyme-relevant herbs.

A 2015 in vitro study (Journal of Applied Microbiology, Goc et al.) found that monolaurin was one of the most effective tested compounds against all morphological forms of Borrelia burgdorferi and Borrelia garinii — spirochetes, round body forms, and biofilms. GML combined with cis-2-decenoic acid also showed synergistic antispirochetal effects. No human clinical trials exist.

Oregano (Origanum vulgare) oil was identified as having significant in vitro activity against B. burgdorferi in the 2023 University of Maryland review—notably the only herb in that review with confirmed anti-borrelia activity but lacking documented anti-inflammatory properties. Carvacrol and thymol in oregano oil disrupt bacterial membranes and eradicate persister cells. It was also active in a 2018 Antibiotics study on essential oils against Borrelia persisters.

Peppermint was included in the 2023 University of Maryland systematic review of 18 herbal supplements for Lyme disease, showing in vitro antimicrobial activity and potent anti-inflammatory properties relevant to persistent Lyme symptoms. Its active constituent menthol and essential oil compounds contribute to antimicrobial effects. It is used in integrative Lyme protocols for symptomatic and anti-inflammatory support.

Quercetin demonstrated bacteriostatic and bactericidal anti-spirochetal effects against B. burgdorferi in in vitro PMC studies. It inhibits NF-κB and pro-inflammatory cytokines relevant to Lyme disease-related inflammation and arthritis. Its biofilm-disrupting properties and ability to potentiate antibiotic effects have been documented. Present in many Lyme-relevant botanicals including Japanese knotweed and Baikal skullcap.

Reishi mushroom (Ganoderma lucidum) was one of 18 herbs evaluated in the 2023 University of Maryland comprehensive Lyme disease review, showing in vitro antimicrobial and strong immunomodulatory activity. It is used in Lyme protocols for immune regulation, inflammation control, and antiviral support. Its triterpenoids and polysaccharides modulate cytokine pathways relevant to chronic Lyme.

Resveratrol, the primary polyphenol of Japanese knotweed (Polygonum cuspidatum), has documented in vitro activity against B. burgdorferi log-phase spirochetes and B. garinii. It inhibits NF-κB-driven pro-inflammatory cytokines, crosses the blood-brain barrier to address neurological Lyme, and inhibits matrix metalloproteinases used by Borrelia for tissue invasion. PMC studies confirm direct anti-spirochetal and anti-inflammatory mechanisms relevant to Lyme disease.

Sweet wormwood (Artemisia annua), source of artemisinin, demonstrated in vitro activity against stationary-phase B. burgdorferi persisters in the 2020 Johns Hopkins Frontiers in Medicine study, outperforming doxycycline. Its synthetic analog artesunate showed improvement in short-term memory impairment in a small Lyme disease pilot study. It has over 2,000 years of traditional medicinal use. Evidence remains primarily in vitro with limited clinical data.

Teasel root (Dipsacus fullonum) has been used in traditional Chinese medicine (Xu Duan) and Western herbalism for Lyme disease, particularly for Lyme arthritis. In vitro studies show lipophilic fractions of Dipsacus sylvestris root inhibit B. burgdorferi growth. A 2022 PMC study identified iridoid sylvestrosides III and IV in teasel leaves as active anti-Borrelia compounds. Evidence is primarily in vitro and traditional; no clinical trials exist.

Thyme (Thymus vulgaris) was identified as one of seven botanicals with in vitro anti-borrelia activity against stationary-phase B. burgdorferi in a comprehensive review. Thymol, its primary active constituent, and carvacrol have documented antimicrobial effects against multiple bacterial forms. It appeared in the 2023 University of Maryland review with confirmed anti-borrelia activity, one of the few herbs beyond the Johns Hopkins 7. Research in Antibiotics (2018) also showed essential oils including thyme eradicate persister cells.

Milk thistle (Silybum marianum) is widely used in integrative Lyme disease protocols for hepatoprotective support, addressing liver stress from both Borrelia toxins and long-term antibiotic therapy. Silymarin (its active flavonolignan complex) has potent antioxidant and anti-inflammatory properties. Over 2,000 years of traditional use for liver protection, with clinical evidence supporting hepatoprotection in drug-induced liver injury applicable to Lyme antibiotic regimens.

Red root is a component of the well-known Buhner Protocol for Lyme disease and co-infections, used specifically to support lymphatic clearance of Borrelia-related debris and address the splenomegaly associated with tick-borne illness. This use is documented in herbal literature and widely adopted in integrative Lyme care. No controlled clinical trials specifically on red root for Lyme disease have been published.

Sarsaparilla (Smilax species) has been used in traditional herbal medicine for Lyme disease for decades, popularized by Stephen Buhner's herbal protocol. It is valued for binding to bacterial endotoxins (lipopolysaccharides) from dying B. burgdorferi, aiding their excretion and reducing the Herxheimer reaction. The 2023 University of Maryland narrative review evaluated sarsaparilla among 18 Lyme-relevant herbs, finding anti-inflammatory but inconclusive direct anti-borrelia evidence.